

Clinical trials support efficacy of tretinoin lotion for Tx of acne

October 16 2018



(HealthDay)—Tretinoin 0.05 percent lotion (ALTRENO Lotion)

provides statistically significant improvement in patients with moderate-to-severe acne, compared to placebo, according to two phase 3 studies published in the October issue of the *Journal of Drugs in Dermatology*.

Stephen K. Tying, M.D., Ph.D., from the University of Texas Health Science Center in Houston, and colleagues evaluated the efficacy, safety, and tolerability of a novel tretinoin 0.05 percent lotion in 1,640 patients with moderate-to-severe [acne](#) aged 9 to 58 years. Patients were randomized to receive either tretinoin 0.05 percent lotion or vehicle.

The researchers found that tretinoin 0.05 percent lotion demonstrated statistically significant superiority to vehicle in reducing inflammatory and non-inflammatory lesion counts (both P

"We believe these new data further demonstrate the value that ALTRENO Lotion provides [patients](#) with acne vulgaris, and we look forward to bringing the product to market by the end of the month," Bill Humphries, president of Ortho Dermatologics, said in a statement.

Several authors report financial ties to the pharmaceutical industry, including Ortho Dermatologics, which manufactures tretinoin. The study was sponsored by Dow Pharmaceutical Sciences.

More information: [Abstract/Full Text \(subscription or payment may be required\)](#)

Copyright © 2018 [HealthDay](#). All rights reserved.

Citation: Clinical trials support efficacy of tretinoin lotion for Tx of acne (2018, October 16) retrieved 2 May 2024 from <https://medicalxpress.com/news/2018-10-clinical-trials-efficacy-tretinoin-lotion.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.